FDA Brief

Warning letters Drugs

FDA warning letter to

Nephron SC Inc.

High riskIssued Oct 11, 2022Posted Oct 25, 2022Office of Pharmaceutical Quality Operations, Division II

Nephron SC's sterile drug manufacturing had unresolved cross-contamination and microbial contamination, making its drugs adulterated.

What happened

FDA inspected Nephron SC's West Columbia, SC drug manufacturing facility from March 28 to April 20, 2022. FDA found inadequate and untimely investigations of cross-contamination—including Bupivacaine found in other drug lots—and process-simulation (media fill) failures with Pseudomonas aeruginosa in blow-fill-seal cooling water, plus deficient environmental monitoring. The firm also failed to submit a required Field Alert Report within three working days; it later submitted FARs and recalled Ketorolac lot 023011 and four outsourcing products.

What FDA found

  1. The firm failed to thoroughly investigate unexplained discrepancies or batch failures, including cross-contamination and microbial contamination.

    21 CFR 211.192
  2. The firm failed to establish and follow written procedures to prevent microbiological contamination and validate aseptic and sterilization processes.

    21 CFR 211.113(b)
  3. The firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas.

    21 CFR 211.42(c)(10)(iv)
  4. The firm failed to submit a Field Alert Report to FDA within three working days after learning of significant drug product changes or deterioration.

    section 505(k) of the FD&C Act, 21 U.S.C. 355(k); 21 CFR 314.81(b)(1)(ii)

What FDA wants

FDA asks the company to provide comprehensive independent assessments and remediation plans for investigations/CAPA, cleaning validation, container closure and BFS equipment, and environmental monitoring, plus specific CAPA for the contamination. The excerpt does not state a response deadline.

Who should pay attention

  • hospitals and clinics using Nephron sterile injectables
  • compounding pharmacies and outsourcing facilities sharing equipment or facilities
  • companies buying sterile drug products from contract manufacturers with mixed 503B and CGMP operations

This is a summary. Read the original letter on fda.gov.

Nephron SC Inc.'s FDA history

Recalls in the last 12 months

Apr 22 Class II Nephron SC, LLC
Drug
Albuterol Sulfate Inhalation Solution, 0.5%, 25 mg/5 mL (5 mg/mL*), 30x5 mL Sterile Unit-Dose Vials, Rx only, nephron 503B Outsourcing facility, 4600 12th Street Extension, West Columbia, SC 29172, NDC 69374-330-05.
Labelling: Illegible label

Full company page

Similar letters to other companies

  1. Baxter International Inc.

    Baxter's Round Lake injectable drug plant violated CGMP (manufacturing quality rules), with cephalosporin cross-contamination and sterile processing failures.

    High risk
  2. Signature Formulations LLC

    FDA warns Signature Formulations about contaminated contract-manufactured drug products and cross-contamination at its Phoenix facility.

    High risk
  3. Shoolin Pharma Chem LLP

    Shoolin Pharma Chem, an Indian API maker, warned over filthy conditions, missing test data, and cleaning failures; all U.S. APIs recalled.

    High risk
  4. Dabur India Limited

    FDA cites Dabur India for falsified records, incomplete lab data, and inadequate cleaning and process validation for over-the-counter drugs.

    High risk